1. Home
  2. |Professionals
  3. |Stephen Bentfield

Stephen Bentfield

Partner
Partner
c2JlbnRmaWVsZEBjcm93ZWxsLmNvbQ==
VCard
VCard

Areas of Focus

Overview

Stephen Bentfield is a partner and a member of the firm’s Health Care Group. Stephen counsels health care organizations on a wide range of health care regulatory and transactional matters. His regulatory experience includes helping clients with issues such as fraud and abuse enforcement risk analysis and mitigation, organizational compliance programs and policies, managed care, value-based care, reimbursement, licensure, and state regulatory issues. On the transactional side, Stephen has extensive experience drafting contracts, advising on deal structuring and negotiation, including the creation of joint ventures and other new corporate structures, as well as mergers and acquisitions.

Before joining Crowell, Stephen served as vice president and group general counsel of DaVita Integrated Kidney Care, the value-based care subsidiary of DaVita Inc. In that role, he led the legal team responsible for structuring, advising, and operating the company’s portfolio of renal-specific accountable care organizations (ACOs), risk-based management services agreements with Chronic Condition Special Needs Plans, commercial risk contracts, and other value-based and integrated care arrangements. His work for DaVita included designing, structuring, and drafting the company’s arrangements with over 50 Kidney Contracting Entities, ESCO joint ventures, and Value-based Enterprises (VBEs), including all accompanying supporting agreements such as provider participation agreements, MSO agreements, and ancillary provider agreements.

Career & Education

    • St. Lawrence University, B.A., 1995
    • Suffolk University Law School, J.D., 2003
    • St. Lawrence University, B.A., 1995
    • Suffolk University Law School, J.D., 2003

    • District of Columbia
    • Massachusetts
    • Colorado
    • District of Columbia
    • Massachusetts
    • Colorado

Stephen's Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....

View All Insights

Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

Client Alert | 6 min read | 06.11.26

CMS Announces New Medicaid Eligibility Requirements: Implications for Managed Care Plans

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

Blog Post | 06.18.25

CMS Innovation Center Releases New Strategy In Line With “MAHA” Agenda

View All Insights

Practices

Stephen's Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....

View All Insights